Description

Mefenamic Tablet

Fenamate NSAID Uterine Antispasmodic & Analgesic

Healthy Life Pharma Private Limited, alongside our specialized global export and marketing division Healthy Inc, is a premier Indian manufacturer, CDMO partner, and wholesale exporter of advanced non-steroidal anti-inflammatory drugs (NSAIDs), gynecology support therapeutics, and acute pain management formulations. We manufacture ultra-high-purity, kinetically stable Mefenamic Acid Tablets inside our state-of-the-art, WHO–GMP certified solid dosage manufacturing installations.

Serving as a foundational therapeutic for primary dysmenorrhea, menorrhagia, and acute muscular distress, this formulation is a massive-volume strategic export to maternity clinic networks, retail pharmacy distribution chains, state healthcare procurement pipelines, and international digital B2B marketplaces across Africa, the CIS region, LATAM, and South-East Asia.

Product Overview

This formulation operates as a “Dual-Action Prostaglandin Pathway Deactivator.” It ensures rapid pain relief and reduces uterine muscle hyper-contractility by cutting off the production of inflammatory markers while simultaneously preventing remaining markers from binding to target smooth muscles.

• Mechanism 1 (Cyclooxygenase Enzyme Inhibition): Mefenamic Acid belongs to the fenamate chemical class. It physically enters inflamed tissues and chemically inhibits Cyclooxygenase-1 and -2 (COX-1 and COX-2) enzymes, stopping the conversion of arachidonic acid into inflammatory prostaglandins ($PGE_{2}$ and $PGF_{2\alpha}$).

• Mechanism 2 (Prostaglandin Receptor Antagonism): Unlike traditional NSAIDs, Mefenamic Acid possesses a distinct secondary mechanism: it physically binds to and competitively antagonizes peripheral prostaglandin receptors located directly on uterine smooth muscle walls.

• Mechanism 3 (Uterine Myometrial Stabilization): This receptor blockade completely neutralizes the muscle-contracting effects of excess prostaglandins. The physical result is an immediate reduction in intrauterine pressure, a decrease in chaotic uterine muscle spasms (antispasmodic effect), and a reduction in local vascular leakage to normalize excessive menstrual blood loss.

Product Composition & Available Strengths

We supply Mefenamic Acid in standard, exact compendial strengths designed to support either acute, low-dose short-term relief or high-potency systemic anti-inflammatory regimens.

Technical & Logistics Specifications

• HS Code: 3004.90.64 (Medicaments containing non-steroidal anti-inflammatory drugs, analgesics, antipyretics) or 3004.90.99 (General Category)

• CAS Number: 61-68-7 (Mefenamic Acid)

• Dosage Form: Oral Solid Film-Coated Tablet (Core matrix precisely film-coated to mask the naturally chalky active powder texture and preserve core stability)

• Packaging Configurations: 10 Tablets per Blister packed in premium, high-barrier Alu-Alu (Cold-Form Foil) or heavy moisture-shield PVC/PVDC strips. Our tropicalized packaging matrices completely block environmental moisture and oxygen transit, guaranteeing a full 36-month shelf life in hot, humid Zone IVb export environments.

Advanced Manufacturing Integrity & Quality Controls

• High-Density Compact Granulation Processing: Mefenamic Acid raw active material possesses naturally low bulk density and poor flow characteristics. We deploy Advanced Roller Compactors and High-Shear Granulators, physically densifying the powder matrix into uniform granules to eliminate weight variations and tablet capping during high-speed compression cycles.

• Taste-Masking Barrier Film Coating: The active raw chemical possesses a bitter, chalky flavor profile that can trigger patient aversion. Our processing lines apply an Advanced Hydroxypropyl Methylcellulose (HPMC) Film Coat, physically isolating the core taste profile without altering gastrointestinal disintegration speeds.

• Validated Rapid Disintegration Kinetics: Every export production batch physically undergoes Automated In-Vitro Dissolution Profiling, chemically verifying that our generic formulations achieve rapid disintegration (under 10 minutes) in gastric fluids to ensure quick systemic absorption and fast pain relief.

Primary Indications

• Gynecology: Treatment of Primary Dysmenorrhea (painful menstrual cramps) and medical management of Functional Menorrhagia (heavy menstrual bleeding) secondary to dysfunctional uterine bleeding profiles.

• Internal Medicine & Rheumatology: Short-term relief of mild-to-moderate Acute Pain, including dental pain, post-operative surgical pain, headaches, and acute inflammatory flares of Osteoarthritis and Rheumatoid Arthritis.

Usage Instructions

• The Post-Meal Timing Mandate: Take the tablet orally with a full glass of water. It must be taken physically with or immediately after a meal to protect the gastric mucosa and reduce gastrointestinal side effects.

• The 7-Day Limitation Rule: Modern clinical guidelines recommend limiting continuous short-term acute usage of Mefenamic Acid to a maximum duration of 7 consecutive days wherever possible (and a maximum of 3 days for standard menstrual cramp cycles), physically minimizing the risk of gastrointestinal or renal side effects.

• Hydration Reinforcement Requirement: Patients must maintain adequate physical fluid intake during active management to ensure optimal renal clearance of the metabolized drug.

Safety Warning: POTENT NSAID & UTERINE ANTISPASMODIC. For Professional Medical Supervision Only. Gastrointestinal Risk Warning: All NSAID compounds carry a chemical risk of inducing local mucosal irritation; monitor for symptoms of gastric ulceration, dyspepsia, or occult bleeding, especially in elderly patient profiles. Renal & Hepatic Note: Periodic tracking of renal function markers and liver enzymes is recommended during prolonged or high-dose therapy runs. Contraindications: Absolute contraindications in patients presenting with active gastrointestinal ulceration or chronic inflammatory bowel disease (IBD), severe renal insufficiency, severe hepatic failure, active coronary artery bypass graft ($CABG$) surgery windows, third-trimester pregnancy, or known hypersensitivity to fenamate or aspirin derivatives.

Global CDMO Services & Wholesale Supply Chain

Healthy Life Pharma Private Limited and Healthy Inc provide comprehensive, internationally validated Third-Party Contract Manufacturing (CDMO Services) and high-volume private label export supply for the entire Mefenamic Acid dosage spectrum. Because this molecule faces zero controlled-substance dual-licensing hurdles, our high-capacity lines can rapidly manufacture, release, and ship multi-container shipping loads. We handle all mandatory documentation (WHO-GMP Certificate, Certificates of Pharmaceutical Product – COPP, Certificates of Analysis – COA, Stability Testing Matrix Sheets, and Complete CTD Format Dossier sets) for seamless entry registration.

Commercial & Bulk Procurement Inquiries:

• Corporate Head Office: Mumbai, Maharashtra, India

• Primary Manufacturing Base: Boisar, Maharashtra, India

• WhatsApp / Direct Call: +91 7710003340

• Corporate Email: info@healthyinc.co.in